{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:00:16Z","timestamp":1781298016619,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ccell.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T14:56:29Z","timestamp":1778165789000},"page":"1121-1123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Minh Truong","family":"Do","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinandos","family":"Skoulidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2026.04.003_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","article-title":"Cholangiocarcinoma 2026: status quo, unmet needs and priorities","volume":"23","author":"Banales","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ccell.2026.04.003_bib2","article-title":"Mechanisms of resistance to active state selective tri-complex RAS inhibitors","author":"Sang","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.ccell.2026.04.003_bib3","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ccell.2026.03.020","article-title":"Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma","volume":"44","author":"Entrialgo-Cadierno","year":"2026","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2026.04.003_bib4","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/2159-8290.CD-24-0421","article-title":"Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer","volume":"14","author":"Araujo","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.04.003_bib5","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c02314","article-title":"Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers","volume":"68","author":"Cregg","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ccell.2026.04.003_bib6","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.21.02752","article-title":"First-in-Human Phase I\/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)","volume":"40","author":"Ou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ccell.2026.04.003_bib7","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","article-title":"A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Singhal","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.04.003_bib8","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2026.04.003_bib9","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1038\/s41591-025-03732-5","article-title":"Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer","volume":"31","author":"Skoulidis","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ccell.2026.04.003_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccell.2025.10.010","article-title":"Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer","volume":"44","author":"Zhang","year":"2026","journal-title":"Cancer Cell"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561082600214X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561082600214X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:27:18Z","timestamp":1781296038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153561082600214X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S153561082600214X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2026.04.003","relation":{},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RAS-ing the bar in the treatment of KRAS-mutant cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2026.03.020","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}